U.S. Postpartum Depression Drugs Market Size & Outlook
U.S. postpartum depression drugs market, 2018-2030 (US$M)
Related Markets
U.S. postpartum depression drugs market highlights
- The U.S. postpartum depression drugs market generated a revenue of USD 285.6 million in 2023 and is expected to reach USD 507.2 million by 2030.
- The U.S. market is expected to grow at a CAGR of 8.5% from 2024 to 2030.
- In terms of segment, postpartum anxiety was the largest revenue generating type in 2023.
- Postpartum Anxiety is the most lucrative type segment registering the fastest growth during the forecast period.
Postpartum depression drugs market data book summary
| Market revenue in 2023 | USD 285.6 million |
| Market revenue in 2030 | USD 507.2 million |
| Growth rate | 8.5% (CAGR from 2023 to 2030) |
| Largest segment | Postpartum anxiety |
| Fastest growing segment | Postpartum Anxiety |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Postpartum Blues, Postpartum Anxiety, Postpartum Obsessive-Compulsive Disorder (OCD), Postpartum Post-Traumatic Stress Disorder (PTSD), Postpartum Panic Disorder, Postpartum Psychosis |
| Key market players worldwide | Sage Therapeutics Inc, Pfizer Inc, Eli Lilly and Co, GSK PLC ADR, Merck & Co Inc, Biogen Inc, Bausch Health Companies Inc, Cipla Ltd DR, Novartis AG ADR, Teva Pharmaceutical Industries Ltd |
Other key industry trends
- In terms of revenue, U.S. accounted for 34.1% of the global postpartum depression drugs market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. postpartum depression drugs market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 62.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Postpartum Depression Drugs Market Scope
Postpartum Depression Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. postpartum depression drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to postpartum depression drugs market will help companies and investors design strategic landscapes.
Postpartum anxiety was the largest segment with a revenue share of 21.99% in 2023. Horizon Databook has segmented the U.S. postpartum depression drugs market based on postpartum blues, postpartum anxiety, postpartum obsessive-compulsive disorder (ocd), postpartum post-traumatic stress disorder (ptsd), postpartum panic disorder, postpartum psychosis covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to U.S. postpartum depression drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. postpartum depression drugs market databook
-
Our clientele includes a mix of postpartum depression drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. postpartum depression drugs market , including forecasts for subscribers. This country databook contains high-level insights into U.S. postpartum depression drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. postpartum depression drugs market size, by type, 2018-2030 (US$M)
U.S. Postpartum Depression Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
